MedPath

PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study

Recruiting
Conditions
Type 2 Diabetes Mellitus
Cardiovascular Disease
Registration Number
NCT06336239
Lead Sponsor
Beijing Anzhen Hospital
Brief Summary

The association between Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) is well established. Traditional risk factors for CVD and CKD are similar, with type 2 diabetes mellitus (T2DM) being the most prevalent risk factor. However, CKD is underdiagnosed and undertreated in patients with CVD. Further understanding of the combination of CKD in CVD patients is important to formulate prevention and treatment strategies for CVD patients and high-risk groups, reduce adverse events in CVD patients, and prevent progression of CKD to End Stage Renal Disease (ESRD).

Detailed Description

The PLACARD study will include approximately 3,000 patients presenting to the cardiology department with type 2 diabetes and cardiovascular disease. The aim of this study was to assess the prevalence of proteinuria (urinary ACR) in type 2 diabetic patients with different cardiovascular diseases, both inpatient and outpatient in the cardiology departments of secondary and tertiary hospitals in China. Participants will be recruited at 30 clinical centers for a period of six months.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
3000
Inclusion Criteria
  • Age ≥18 years old;
  • Diagnosed T2DM combined with ≥1 CVD (hypertension, coronary heart disease, atrial fibrillation, heart failure);
  • During the data collection period, they went to the outpatient clinic of the cardiology department of the research center, or received treatment in the cardiology department;
  • Ability to self-sign informed consent (electronic /paper).
Exclusion Criteria
  • Pregnant or lactating women;

  • Dialysis patients;

  • Other diseases that lead to elevated albuminuria, such as severe infection, confirmed primary glomerular disease, etc.;

    . Malignant tumors being treated (surgery, chemotherapy, radiotherapy or targeted therapy);

  • Cachexia (CSS score ≥ 5 points);

  • Severe liver disease (Child- Pugh grade C) ;

  • Participated in an interventional clinical trial in the past three months.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The prevalence of albuminuriaOn the day of patients enrollment.

To assess the prevalence of albuminuria in patients who are combined with type 2 diabetes mellitus and different cardiovascular diseases in inpatient and outpatient cardiology departments of secondary and tertiary hospitals in China.

Secondary Outcome Measures
NameTimeMethod
Evaluate the management of patients with type 2 diabetes mellitus and cardiovascular disease across different levels of cardiology departments in hospitals.On the day of patients enrollment.

Collect clinical assessment data from patients (including test results and the frequency of these tests over the past year), and assess the management of patient-related risk factors and complications by physicians in hospitals of different levels based on the frequency of testing.

Lthe prevalence of microalbuminuria and macroalbuminuria evels of microalbuminuria and macroalbuminuriaOn the day of patients enrollment.

To evaluate the levels of microalbuminuria and macroalbuminuria of patients with type 2 diabetes mellitus (T2DM) in inpatients and outpatients cardiology departments;

The prevalence of microalbuminuria and macroalbuminuriaOn the day of patients enrollment.

To evaluate the prevalence of microalbuminuria and macroalbuminuria in patients with T2DM complicated with different cardiovascular diseases

To evaluate the related influence factors of albuminuria and the treatment patterns of CKD patients and non-CKD patients in cardiology departments;On the day of patients enrollment.

After outpatient patients receive feedback on their renal function tests, assess whether physicians prescribe new relevant medical orders by recording them. Evaluate the treatment patterns for CKD and non-CKD patients in the cardiology department.

Trial Locations

Locations (27)

Peking University Third Hospital

🇨🇳

Beijing, Beijing, China

Beijing Sixth Hospital

🇨🇳

Beijing, Beijing, China

Chinese PLA Army Characteristic Medical Center

🇨🇳

Chongqing, Chongqing, China

Luoyang Sixth People's Hospita

🇨🇳

Luoyang, Henan, China

Haidong City Second People's Hospital

🇨🇳

Haidong, Gansu, China

First Hospital of Hebei Medical University

🇨🇳

Shijia Zhuang, Hebei, China

Zhangjiagang Sixth People's Hospital

🇨🇳

Zhangjiagang, Jiangsu, China

Shenyang Ninth People's Hospital

🇨🇳

Shenyang, Liaoning, China

Tai'an First People's Hospital

🇨🇳

Tai'an, Shandong, China

Jining First People's Hospital

🇨🇳

Jining, Shandong, China

Shenyang Tenth People's Hospital

🇨🇳

Shenyang, Liaoning, China

Jing'an District Central Hospital of Shanghai

🇨🇳

Shanghai, Shanghai, China

Zhongshan Hospital Fudan University Qingpu Branch

🇨🇳

Shanghai, Shanghai, China

Qinyuan County People's Hospital

🇨🇳

Changzhi, Shanxi, China

Shanxi Bethune Hospital

🇨🇳

Taiyuan, Shanxi, China

The First Affiliated Hospital of Xi'an Jiaotong University

🇨🇳

XI Ail, Shanxi, China

The Fifth People's Hospital of Sichuan Province

🇨🇳

Chendu, Sichuan, China

Taizhou Central Hospital

🇨🇳

Taizhou, Zhejiang, China

West China Hospital of Sichuan University

🇨🇳

Chengdu, Sichuan, China

Fangshan District First Hospital

🇨🇳

Beijing, Beijing, China

Ruyang County People's Hospita

🇨🇳

Luoyang, Henan, China

Yongcheng People's Hospital

🇨🇳

Yongcheng, Henan, China

The First Affiliated Hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

Weihai Central Hospital

🇨🇳

Weihai, Shandong, China

The First Affiliated Hospital of Xinjiang Medical University

🇨🇳

Ürümqi, Xinjiang, China

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

The First Affiliated Hospital of Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath